Strides Arcolab gets USFDA nod for generic anti-cancer drug

Pharma firm Strides Arcolab today said its subsidiary Onco Therapies Ltd has received final approval from the US health regulator for its generic version of Oxaliplatin injection used for treating cancer.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead Masteryourmoney Earnings
moneycontrol.com

Home » News » Business

Aug 08, 2012, 05.59 PM | Source: PTI

Strides Arcolab gets USFDA nod for generic anti-cancer drug

Pharma firm Strides Arcolab today said its subsidiary Onco Therapies Ltd has received final approval from the US health regulator for its generic version of Oxaliplatin injection used for treating cancer.

Like this story, share it with millions of investors on M3

Strides Arcolab gets USFDA nod for generic anti-cancer drug

Pharma firm Strides Arcolab today said its subsidiary Onco Therapies Ltd has received final approval from the US health regulator for its generic version of Oxaliplatin injection used for treating cancer.

Post Your Comments

Share Cancel

Pharma firm Strides Arcolab today said its subsidiary Onco Therapies Ltd has received final approval from the US health regulator for its generic version of Oxaliplatin injection used for treating cancer.
    
The nod from the US Food and Drug Administration is for Oxaliplatin injection in strengths of 50mg/10ml and 100mg/20ml, the company said in a statement.
    
"The company had in November 2011 received tentative approval from USFDA based on a Para III filing. This approval was later converted to a Para IV filing based on which USFDA has now granted final approval," it added.
    
A company usually makes a Para III filing when it does not have any plans to sell the generic drug until the expiry of the original patent, whereas a Para IV filing is made when it believes that its generic product does not infringe innovator's patent.
    
Citing IMS data, Strides said the US market for generic Oxaliplatin is approximately USD 1.5 billion.
    
"Oxaliplatin is part of the oncology portfolio licensed to Pfizer for the US market and the product is available for immediate launch," the company added.
    
Oxaliplatin is a chemotherapy drug used to treat advanced cancer of the colon and rectum. It is used in combination with other medications to slow or stop cancer cell growth.
     
Strides' scrip was trading at Rs 757.85 on the BSE in the afternoon, up 4.62% from previous close.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Strides Arcolab gets USFDA nod for generic anti-cancer drug

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login